Joseph Carroll
Comptroller/Controller/Auditor bij RENOVACOR, INC.
Profiel
Joseph Carroll is currently working as the Secretary, Chief Accounting Officer & Senior VP at Renovacor, Inc. Prior to his current position, he worked as the Associate Director-Finance at Idera Pharmaceuticals, Inc. from 2017 to 2021.
Mr. Carroll completed his undergraduate degree at West Chester University of Pennsylvania.
Actieve functies van Joseph Carroll
| Bedrijven | Functie | Begin |
|---|---|---|
| RENOVACOR, INC. | Comptroller/Controller/Auditor | 17-06-2022 |
Eerdere bekende functies van Joseph Carroll
| Bedrijven | Functie | Einde |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01-06-2021 |
Opleiding van Joseph Carroll
| West Chester University of Pennsylvania | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
